1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Nektar Therapeutics

Nektar Therapeutics

NKTR
Nektar TherapeuticsUS flagNASDAQ Global Select
38.75
USD
+2.11
- -
1.11BMarket Cap

Total Valuation

Nektar Therapeutics carries a market capitalization of 1.11B, placing it among publicly traded companies globally. Its enterprise value stands at 1.78B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap1.11B
Enterprise Value1.78B

Share Statistics

Nektar Therapeutics currently has 34.13M shares outstanding.

Shares Outstanding34.13M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 31.02, and the price-to-book ratio stands at 2.64.

PE RatioN/A
PS Ratio31.02
PB Ratio2.64
P/TBV Ratio2.64
P/FCF Ratio-7.25
P/OCF Ratio-7.24

Enterprise Valuation

EV / Sales32.55
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Nektar Therapeutics maintains a current ratio of 10.42, meaning it holds 10.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.70, indicating elevated leverage, while an interest coverage ratio of -4.20 demonstrates limited ability to service its debt obligations.

Current Ratio10.42
Quick Ratio9.71
Debt / Equity8.70
Debt / EBITDA-0.60
Interest Coverage-4.20

Financial Efficiency

Return on Equity (ROE)-451.78
Return on Assets (ROA)-24.12
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Income Tax64,000.00
Effective Tax RateN/A

Stock Price Statistics

Nektar Therapeutics's stock has declined approximately -38.4823% over the past 52 weeks. The 50-day moving average sits at 62.22, while the 200-day moving average is 65.12.

Beta (5Y)N/A
52-Week Price Change-38.4823%
50-Day Moving Average62.22
200-Day Moving Average65.12
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Nektar Therapeutics generated 54.59M in revenue and converted that into -157.13M in net income, yielding earnings per share of -6.48. EBITDA reached -129.95M, while operating income came in at -130.64M.

Revenue54.59M
Gross Profit33.60M
Operating Income-130.64M
Pretax Income-153.11M
Net Income-157.13M
EBITDA-129.95M
EBIT-130.64M
Earnings Per Share (EPS)-6.48

Balance Sheet

Nektar Therapeutics holds 684.34M in cash and equivalents against 78.56M in total debt, resulting in a net debt position of -39.27M. Total book value stands at 903.12M, with working capital of 668.42M providing operational flexibility.

Cash & Cash Equivalents684.34M
Total Debt78.56M
Net Debt-39.27M
Equity (Book Value)903.12M
Book Value Per Share26.46
Working Capital668.42M

Cash Flow

Nektar Therapeutics produced -233.79M in operating cash flow over the past twelve months. After subtracting -244,000.00 in capital expenditures, free cash flow totaled -234.03M - equivalent to -9.65 per share.

Operating Cash Flow-233.79M
Capital Expenditures-244,000.00
Free Cash Flow-234.03M
FCF Per Share-9.65

Margins

Nektar Therapeutics operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -239.32 and net profit margin of -287.84 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin-239.32
Pretax Margin-280.49
Profit Margin-287.84
EBITDA Margin-238.05

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-45.10
FCF Yield-13.79

Stock Splits

Nektar Therapeutics's most recent stock split took place on June 9, 2025 with a 15:1 split ratio.

Last Split Date6/9/2025
Split Ratio15:1

Scores

Nektar Therapeutics posts an Altman Z-Score of 2.92, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.92